Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.74 +1.42 (+2.67%)
Streaming Delayed Price Updated: 2:06 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 817,226
Open 53.32
Bid (Size) 54.71 (100)
Ask (Size) 54.76 (100)
Prev. Close 53.32
Today's Range 53.01 - 55.00
52wk Range 49.26 - 66.28
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive resu... 
Via StockStory

Performance

YTD
-7.9%
-7.9%
1 Month
-1.3%
-1.3%
3 Month
-6.5%
-6.5%
6 Month
+1.6%
+1.6%
1 Year
-4.0%
-4.0%

More News

Read More
News headline image
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
Via StockStory
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth ↗
Via Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance ↗
Via Chartmill
Topics Earnings
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock ↗
Via Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down
Via StockStory
Topics Credit Cards
News headline image
BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook
Via StockStory
News headline image
BioMarin (BMRN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates
Via StockStory
News headline image
BioMarin (BMRN) Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
Via MarketMinute
Topics Economy
News headline image
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
Via StockStory
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
Via StockStory
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
Via The Motley Fool
News headline image
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
Via The Motley Fool
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
Via The Motley Fool

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 54.74
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 06/03/26 02:06 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 10.04B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.